LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Kamuriwo, D. S.; Baden-Fuller, C. (2014)
Languages: English
Types: Article
Subjects: HD28
The case focuses on Ken Powers, cofounder and chief executive officer of Sparrow Therapeutics, whose young biotechnology company has reached a critical stage where he has to decide whether or not to sell. The company's three main sets of investors have different priorities: (1) a quick cash sale now, (2) delay sale for about a year if returns are greater, and (3) delay sale for 2 years, build company value, and retain autonomy. What choice would be best for the company, for its investors-and for Ken himself? And when would be the best time to implement the exit strategy?
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 8 Unibio Angel backed company Ventures
    • 9 Biotech Biotech Services Services company Management Team Stuart Cocks Research Director (Joined 2000 ) Sue Gaither Clinical Development Director (Joined May 2001) Ian Phelps CFO (Joined in June 2001) Barbra Commercial Director Domain (Joined 2003) Exhibit 9: Potential suitors list as at June 2006 HQ and size (employees) in 2005 Revenues in 2005 $52 billion Net Profits in 2005 $11 billion Antiviral Capabilities and markets? Yes, well represented $23 billion
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article